News

  Malaria is one of the world’s three most deadly infectious diseases. The World Health Organization (WHO) and a host of other organizations and funds have been set up to eradicate the disease. Estimates for 2011 indicate that some 3.3 billion people are at risk of contracting malaria, a disease that each year affects some 219 million people and is reportedly responsible for around 660,000 deaths².

  Emerging markets are a key focus for Sysmex. As our business develops in these markets, we aim to contribute to advances in healthcare that can address serious infectious diseases that are rife in many countries.

  The technology that Sysmex has developed uses the white blood cell analysis technology employed in the XN-Series and XS-Series Automated Hematology Analyzers, using flags to show when blood cells change shape, which tends to occur during P. vivax and P. malariae infection. We expect this technology to be employed mainly in South Asia. Previous testing methods occasionally delivered inaccurate white blood cell counts when testing blood infected with P. vivax and P. malariae; Sysmex’s newly developed analysis technology enables accurate white blood cell counting and differentiation. In the hematology field, we expect this technology to be used in screening exams for P. vivax and P. malariae.

  Going forward, Sysmex is aiming to continue promoting the development of technologies that will further increase the quality and efficiency of testing, including for malaria. By responding to increased worldwide demand for testing and increasingly sophisticated testing needs, we will contribute to developments and advances in healthcare.